Moderna Inc said on Tuesday its COVID-19 vaccine produced neutralizing antibodies against emerging variants, including the delta variant first identified in India, in a lab study.

Data was reported from blood serum from eight participants obtained one week after they received the second dose of the vaccine in an early-stage trial.